Quick answer
The future of regenerative medicine led by EHL BIO focuses on using cell therapy to address challenging conditions, particularly neurological, chronic kidney, and degenerative joint issues. Through world-class research and production standards, we aim for rehabilitation and healthy aging (Aging Well) based on EHL team assessments.
Key takeaways
- Leader in cell separation and culture technology, yielding 1,000 times higher output than standard yields.
- GMP-standard Class 100 manufacturing facility supporting 6,000 lots per year.
- Certified as the first Human Cell Management Business in South Korea.
- Ongoing research and clinical trial projects supported by consistent funding.
Vision for the Future: Regenerative Medicine for Humanity
Founded in 2012, EHL BIO aims to be a leading research institute finding solutions for diverse health conditions and aging-related issues. Under the leadership of CEO MD Hong-gi Lee, we are committed to merging medical and pharmaceutical technologies to develop advanced regenerative medicine. Our primary goal is to enhance quality of life and help people achieve healthy longevity (Aging Well).
Our operations span from fundamental research to restorative application, focusing on neurological, metabolic, and immune rehabilitation. These technologies represent the core of next-generation biologics, set to expand healthcare options in the near future.
GMP Manufacturing Standards and Robust Technology
EHL BIO's distinction lies in its specialized cell separation and culture technology, which maintains excellent cell survival rates and produces 1,000 times higher yields than standard methods. The entire process takes place within our research center, equipped with Class 100 GMP-standard facilities and a comprehensive cell storage system at -196°C.
We were certified as the first Human Cell Management Business in South Korea under the Modern Regenerative Medicine and Biopharmaceuticals Act. This certification confirms our adherence to high safety and quality control standards, from sample collection and inspection to cell processing for research and restorative services.
We are committed to leading biotechnology that benefits humanity through advanced regenerative medicine for a better quality of life.
Major Milestones in Stem Cell Therapy for Kidney and Skin Health
EHL BIO has achieved significant success in stem cell drug development. KDSTEM, derived from urine and expressing Klotho protein for kidney conditions, received IND approval for Phase 1 clinical trials in 2023 and has been consistently selected for regenerative medicine projects. This offers new options for those seeking kidney health restoration.
Furthermore, ADSTEM for Atopic Dermatitis has progressed to Phase 3 clinical trials following positive Phase 2 results in managing severity and inflammation. This marks a significant step in using autologous adipose-derived stem cells to effectively modulate the immune system.
Exosome Innovation and Research Collaboration
Beyond direct cell therapy, EHL BIO leads in developing Exosomes—nano-sized vesicles that facilitate cell communication and tissue regeneration. We launched 'Klosome,' combining Klotho protein with Exosomes to promote quality of life and skin restoration. Research also focuses on using Exosomes to support long-term wellness.
These achievements are driven by a robust network of over 100 partner hospitals in South Korea, along with collaborations with top universities and research institutes. This ensures the delivery of advanced medical innovations to our clients.
Frequently asked questions
What makes EHL BIO's cell production unique?
EHL BIO features proprietary cell culture technology yielding 1,000 times higher output than standard yields, supported by a Class 100 GMP facility capable of producing 6,000 lots annually.
What are the goals of restoration with EHL BIO's stem cells?
ADSTEM for Atopic Dermatitis is in Phase 3 clinical trials, while KDSTEM for kidney conditions is in Phase 1-2, both focusing on restorative goals and quality of life under rigorous research.
How can clients in Thailand access EHL BIO's services?
EHL Thailand provides a Thai coordination team to assist with medical document evaluation, travel planning, and post-service follow-up after visiting the EHL Cell Center in South Korea.
Related conditions
Based on EHL BIO information: EHL BIO · EHL BIO · EHL BIO · EHL BIO. Each care plan follows an individual EHL assessment.
